MorphoSys AG Asset Profile

= Subscriber Access Only

You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.

Year established

1992

Location

Planegg Germany

Primary Industry

Biotechnology

About

Founded in 1992 and based in Planegg, Germany, MorphoSys AG is a biotechnology company that mainly develops and provides pharmaceutical medicine for cancer diseases. It was founded in Martinsried, Germany by Dr. Simon Moroney and Prof. Dr. Andreas Plückthun. Initially, MorphoSys served as an R&D technology provider, but it quickly evolved into a biopharmaceutical powerhouse. MorphoSys has forged multiple partnerships and collaborations with many pharmaceutical companies such as Novartis, Janssen, Schering-Plough, Pfizer, and Merck over the years. In February 2024, Novartis International AG agreed to acquire MorphoSys AG from Royalty Pharma Plc for EUR 2.7 billion or EUR 68 per share in cash in a public-to-private transaction. MorphoSys has leveraged its proprietary HuCAL technology to build a diverse pipeline of therapeutic antibody candidates. The company's lead product, Monjuvi (tafasitamab-cxix), is a humanized monoclonal antibody approved for the treatment of diffuse large B-cell lymphoma, a type of blood cancer. Monjuvi was developed in collaboration with Incyte Corporation and generated net product sales of $92 million in 2023. In addition to Monjuvi, MorphoSys has several other drug candidates in its pipeline. Pelabresib, an investigational BET inhibitor, as of 2024, is in Phase 3 clinical trials for the treatment of myelofibrosis, a rare and serious blood cancer. Tulmimetostat, an investigational next-generation dual inhibitor of EZH2 and EZH1, is being evaluated in a Phase 2 study for the treatment of advanced solid tumors and hematologic malignancies in 2024. MorphoSys's revenue streams include product sales, royalties, and licensing agreements. The company also generates revenue from licensing its HuCAL technology to other pharmaceutical and biotechnology companies. The acquisition in 2024 will help MorphoSys AG to continuously enhance its pharmaceutical production, and accelerate its product opportunities in the biotechnology sectors.

Primary Industry

Biotechnology

Sub Industries

Biopharmaceuticals, Pharmaceutical Research & Development, Specialty Pharmaceuticals

Website

www.morphosys.com

Verticals

Manufacturing

Total Amount Raised

Subscriber access only

Time to go Pro

Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.